PMC:7696151 / 92268-92439 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"2764","span":{"begin":42,"end":53},"obj":"Chemical"}],"attributes":[{"id":"A2764","pred":"tao:has_database_id","subj":"2764","obj":"MESH:D002443"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In some cases, prophylaxis of intravenous ceftriaxone (2g/day) for the first two weeks followed by HCQ/DXC for at least 12–18 months has been recommended [72,159,160,161]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T587","span":{"begin":0,"end":171},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In some cases, prophylaxis of intravenous ceftriaxone (2g/day) for the first two weeks followed by HCQ/DXC for at least 12–18 months has been recommended [72,159,160,161]."}